Ann: INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPY, page-18

  1. 14,314 Posts.
    lightbulb Created with Sketch. 4260
    Did finally the penny drop?

    65% improvement is huge. Imagine what just 30% would mean to a stage 4 patient. So far there are many monoclonal PD1 inhibitors trialed and a few on the market selling for multi billion USD. But almost all come with serious side effects, don't last unless constantly re-administered and have no observed / reported triggered immune system memory effect. From my research only IVX 043 pre-clinical and IMU's CF33 / Her-Vaxx and PD1-Vaxx in clinical trials have ever achieved that.

    GLTA
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.5¢
Change
-0.001(1.04%)
Mkt cap ! $8.114M
Open High Low Value Volume
9.6¢ 9.6¢ 9.5¢ $2.942K 30.75K

Buyers (Bids)

No. Vol. Price($)
2 66962 9.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.6¢ 29244 1
View Market Depth
Last trade - 15.01pm 08/08/2025 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.